Curcumin differentially affects cell cycle and cell death in acute and chronic myeloid leukemia cells
- Center of Studies and Advance Research, Mexico City (Mexico)
- National Institute Polytechnique, Mexico City (Mexico)
- National Autonomous University of Mexico (UNAM), Mexico City (Mexico); Hospital General, Mexico City (Mexico)
- Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States); Univ. of California, Davis, CA (United States)
- National Institute of Genomic Medicine, Mexico City (Mexico)
Curcumin is a phytochemical with potent antineoplastic properties. The antitumoral effects of curcumin in cells derived from chronic or acute myeloid leukemia have been already described. However, a comparative study of the cytostatic and cytotoxic effects of curcumin on chronic and acute myeloid leukemia cells has not yet been performed. In the present study, the cellular effects of curcumin on cell lines derived from chronic or acute myeloid leukemia were examined. Dose and time-response assays were performed with curcumin on HL-60 and K562 cells. Cell viability was evaluated with trypan blue exclusion test and cell death by flow cytometry using a fluorescent molecular probe. Additionally, a cell cycle profile was analyzed, and protein markers of cell cycle progression and cell death were investigated. In the present study, the K562 cells showed a higher sensitivity to the cytostatic and cytotoxic effects of curcumin compared with HL-60. In addition, curcumin induced G1 phase arrest in HL-60 cells and G2/M phase arrest in K562 cells. Furthermore, curcumin-related cell death in HL-60 was associated with the processed forms of caspases-9 and -3 proteins, whereas in K562 cells, both the processed and the unprocessed forms were present. Accordingly, activity of these caspases was significantly higher in HL-60 cells compared with that in K562. In conclusion, curcumin elicits different cellular mechanisms in chronic or acute myeloid leukemia cells and the powerful antitumoral effect was more potent in K562 compared with HL-60 cells.
- Research Organization:
- Lawrence Livermore National Laboratory (LLNL), Livermore, CA (United States)
- Sponsoring Organization:
- Consejo Nacional de Ciencia y TecnologĂa (CONACyT); USDOE National Nuclear Security Administration (NNSA)
- Grant/Contract Number:
- AC52-07NA27344
- OSTI ID:
- 1880958
- Report Number(s):
- LLNL-JRNL-778997; 973039
- Journal Information:
- Oncology Letters, Journal Name: Oncology Letters Journal Issue: 5 Vol. 15; ISSN 1792-1074
- Publisher:
- Spandidos PublicationsCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent
Potent antitumor activities of recombinant human PDCD5 protein in combination with chemotherapy drugs in K562 cells
Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia
Journal Article
·
Thu Feb 04 23:00:00 EST 2016
· Biochemical and Biophysical Research Communications
·
OSTI ID:22594222
Potent antitumor activities of recombinant human PDCD5 protein in combination with chemotherapy drugs in K562 cells
Journal Article
·
Fri May 28 00:00:00 EDT 2010
· Biochemical and Biophysical Research Communications
·
OSTI ID:22202608
Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia
Journal Article
·
Thu Feb 09 23:00:00 EST 2006
· Biochemical and Biophysical Research Communications
·
OSTI ID:20798790